Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells

@article{Ruan2012ProgestogensAM,
  title={Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells},
  author={Xiangyan Ruan and Hans J Neubauer and Y T Yang and Helen Schneck and Silke Schultz and Tanja N. Fehm and Michael A. Cahill and Harald Seeger and Alfred Otto Mueck},
  journal={Climacteric},
  year={2012},
  volume={15},
  pages={467 - 472}
}
ABSTRACT Objectives Evidence is accumulating that progestogens may play a crucial role in the development of breast cancer under contraception and hormone therapy in reproductive and menopausal women. Progesterone receptor membrane component 1 (PGRMC1) expressed in breast cancer may be important in tumorigenesis and thus may increase breast cancer risk. The aim of this project was to investigate the influence of progesterone and nine synthetic progestins on MCF-7 breast cancer cells… 
Progestogens and PGRMC1-dependent breast cancer tumor growth: An in-vitro and xenograft study.
TLDR
PGRMC1 increases the breast-cell proliferation effects of certain progestogens, including dydrogesterone, in contrast to progesterone, but not during estradiol-induced proliferation, either in vitro or in a xenograft animal model, in Contrast to norethisterone.
Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells
  • H. Schneck, X. Ruan, +4 authors H. Neubauer
  • Biology, Medicine
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2013
TLDR
DNG increased proliferation alone and in combination with low E2 concentrations, thus a progestogen-derived breast cancer risk cannot be excluded at least in women overexpressing PGRMC1.
Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1.
TLDR
A significant proliferative effect of MPA is demonstrated when combined with high concentrations of growth factors, more pronounced in breast cancer cells overexpressing PGRMC1.
The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: A xenograft model.
TLDR
This is the first comparison of both progestogens in vivo using nude mice, which are frequently used in xenograft models to determine whether women with overexpression of PGRMC1 are at increased risk of breast cancer if NET instead of progesterone is used in MHT.
Possible role of PGRMC1 in breast cancer development
TLDR
Investigations point towards an important role of estrogen receptor-α in the signaling cascade, resulting in the proliferative effect induced by progestins, and activation of PGRMC1 may explain the increased breast cancer risk observed during treatment with certain progESTins.
Membrane-initiated effects of Serelys® on proliferation and apoptosis of human breast cancer cells
TLDR
Serelys® appears to trigger no further breast cancer risk when applied in the post menopause to women, who do or do not overexpress PGRMC1, and may be an effective alternative for alleviating postmenopausal symptoms without increasing Breast cancer risk.
Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors.
TLDR
It is demonstrated that PGRMC1 plays a prominent role in the growth and chemoresistance of human endometrial tumors and promotes tumor cell viability during chemotherapeutic stress.
PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol
TLDR
PGRMC1 increases strongly the estrogen-dependent breast cell proliferation, and not only could predict the risk using progestogens but also of different estrogens.
PGRMC1 Promotes Progestin-Dependent Proliferation of Breast Cancer Cells by Binding Prohibitins Resulting in Activation of ERα Signaling
Simple Summary Combined menopausal hormone therapy is associated with increased breast cancer risk in postmenopausal women. In our previous studies, progesterone receptor membrane component 1
Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors
TLDR
Findings indicate that PGRMC1 plays an important role in regulating the growth and survival of TNBC cells in vitro and ultimately in the formation and development of these tumors in vivo, and may be a therapeutic target for TNBCs.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
New insight on a possible mechanism of progestogens in terms of breast cancer risk
TLDR
Progesterone appears to act neutrally, whereas MPA, NET and DRSP trigger proliferation and thus might increase breast cancer risk, whereas PGRMC1 mediates a progestogen-dependent proliferative signal in MCF-7 cells.
The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells.
TLDR
The in vitro results indicate that the influence on breast cancer risk using HRT in postmenopausal women might depend on the type of progestin used as well as on the regimen applied, and whether progesterone and various synthetic C19- and C21-progestins in general can reduce cancer risk in long-term treatment remains uncertain.
Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells
  • H. Neubauer, G. Adam, +5 authors T. Fehm
  • Biology, Medicine
    Climacteric : the journal of the International Menopause Society
  • 2009
TLDR
PGRMC1 is expressed in breast cancer tissue and mediates an RU-486-independent proliferative signal, which might also contribute to VEGF-induced neovascularization in tumor tissue.
Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines.
TLDR
Failure to respond to progestin treatment may be due to the very heterogeneous nature of human breast tumors and to the inability of these molecules to interfere with the IGF-R pathway.
Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition
TLDR
The results indicate that equine estrogens have a proliferative action similar to that of 17β-estradiol, and progesterone has no deleterious effect even at pharmacological levels, in contrast to progestogens.
Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.
TLDR
Direct evidence is provided that the 19-nortestosterone derivatives in OC have estrogenic properties and suggests that activation of ER, but not progesterone receptor, is the growth-stimulatory mechanism for these synthetic progestins.
The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells.
TLDR
Certain progestogens are able to induce proliferation of or inhibit growth of benign or malignant human breast epithelial cells independently of the effects of growth factors and E2; therefore, choice of progestogen for hormone therapy may be important in terms of influencing possible breast cancer risk.
Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.
TLDR
These studies suggest that the 19-norprogestins norgestrel and gestodene stimulate MCF-7 breast cancer cell growth by activating the oestrogen receptor.
Differential effects of progestogens on breast cancer cell lines.
TLDR
In vitro results indicate that not all progestogens act equally on breast cancer cells, while some (dihydrodydrogesterone (DHD), the active metabolite of dydrogestone, tibolone and progesterone (Prog) alone or combined with estradiol induce apoptosis.
Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells
TLDR
The data on NOM as compared to other progestins are consistent with their antiproliferative effects on human breast cancer cells grown in estrogenic conditions.
...
1
2
3
4
5
...